

In the Drawings

As indicated by red ink on the attached drawings and as set forth in a separate letter to the Official Draftsperson, please amend the drawings as follows:

Please replace with newly submitted "Figure 3".

REMARKS


In this amendment, specification has been amended to render the application more legible and to correct informalities. Figure 3 has been replaced to add Sequence ID Numbers.

CONCLUSION

Applicants believe all the pending claims are now in condition for examination. Applicants assert that no new matter has been added in this amendment. Entry of the Preliminary Amendment is respectfully requested. If the Examiner feels that a telephone conference would in any way expedite the prosecution of the application, please do not hesitate to call the undersigned at (408) 731-5000.

Respectfully submitted,

Date: 5-1-2002



Wei Zhou

Legal Department
Affymetrix, Inc.
3380 Central Expressway
Santa Clara, CA 95051

Tel: 408/731-5000/Fax: 408/731-5392

Serial No.: 09/683,258

Filing Date: 12/05/2001

MARKED UP VERSION OF AMENDMENTS**In the Specification**

Please replace paragraph 0006 with the following:

In yet additional aspect, methods for analyzing gene expression regulation are provided. The methods include obtaining a first set of candidate fragments from the genomic DNA of a first sample, where the first sample is a control sample; obtaining a second set candidate fragments from the genomic DNA of a second sample, wherein the second sample is treated; and comparing the first and second sets of candidate fragments. The candidate fragments can be obtained using DNA foot printing technology. [t]The second sample may be treated with a pharmaceutical agent or with an environmental change. The step of comparing candidate fragments may include hybridizing the first and second sets of candidate fragments with the same collection of nucleic acid probes. In some other embodiments, the step of comparing candidate fragments may include hybridizing the first and second sets of candidate fragments with a first and second collections of nucleic acid probes. The first and second collection of nucleic acid probes can be the same. The nucleic acid probes may be immobilized on a collection of beads or optical fibers or on a substrate. Preferably, the collection of nucleic acid probes contains at least 10,000, 50,000, 100,000, or 1,000,000 probes. The nucleic acid probes may be oligonucleotide probes, preferably between 10-50 in length. In some embodiments, the probes tile genomic sequences of interest. In preferred embodiments, at least one of the binding proteins is unknown.

Please replace paragraph 0007 with the following:

The accompanying drawings, which are incorporated in and form a part of this specification, illustrate embodiments of the invention and, together with the description, serve to explain the principles of the invention: